

28 April 2020

To whom it may concern

Re Haines Disposable Curtains

Recent studies are showing the virus behind a current pandemic, the human Coronavirus (COVID19) is a viral illness where the cell structure mimics those of measles and Swine flu (H1N1).

Haines Disposable Curtains are coated with a solution of nanometer silver and quaternary ammonium silicon compounds acting as a proven strong antiviral, antifungal and antibacterial agents (3,4,5). The coating works by trapping the pathogens, preventing them from multiplying and effectively killing them.

The United States Environmental Protection Agency (EPA)

List N: Disinfectants for Use Against COVID19 (287 items) Incl;

- Quaternary Ammonium Compounds
- Silver nanoparticles

(3)

Silver Nanoparticles (AgNPs) as an antiviral agent			
Influenza virus (H7N3)	Orthomyxoviridae	Proven	
Transmissible gastroenteritis virus (TGEV)	Coronaviridae	Proven	
Respiratory syncytial virus	Paramyxoviridae	Proven	
Monkeypox virus	Poxviridae	Proven	

(4,6)

26 Heath Street, Lonsdale South Australia 5160 **T** 08 8294 5999 **F** 08 8294 4337 E sales@hainesmedical.com.auW hainesmedical.com.au





















HAINES® MEDICAL AUSTRALIA. ALWAYS THINKING. ALWAYS THERE.

Specialists in Disposable and Single Patient Use products



The results at the time of writing indicate that with the chemical components of the material in the curtains and current recommendations to replace soiled or damaged Disposable Curtains immediately makes the Haines Disposable Curtain a cost-effective option in controlling the viral and bacterial load in the environment (2).

Tests have shown the coating to be effective for up to two years. Each curtain is labelled for easy tracking of fitting and change dates.

The current guidelines from Haines, found below, are up to date and relevant.

Area	Recommended changeover frequency of Haines® Disposable Curtains	For comparative purposes, recommended changeover of Reusable Curtains as per [NHMRC 2010]
Very High Risk Outbreaks of infectious diseases or gastroenteritis. Patients with Carbapenem Resistant Enterobacteriaceae (CRE) or Novel emerging pathogen i.e. Ebola	Change immediately and upon discharge of the patient/client from bed or room and dispose	Change immediately and upon discharge of the patient/client
High Risk Intensive care units High dependency unit Burns unit, renal units Day surgery Operating suites Emergency wards Wards for patients/clients with highly transmissible diseases requiring transmission based precautions e.g. MROs (VRE, MRSA, S.aureus, E.Coli) Patients with Clostridium difficile (C. Diff)	Annually - Change annually or if they are visibly soiled or torn	Monthly - Change monthly or change upon discharge if MRO (Multi-Resistant Organisms) present. If visibly soiled change immediately.

NOTE: Upon consultation with a clinical infection control manager, general advice pertaining to the maintenance of MediCurtains **during a viral outbreak** (such as COVID-19 at present), staff should change the curtains when the patient is discharged from the room or cubicle and disposed as per your facility guidelines.

Please note that hand hygiene as well as environmental cleaning are two critical factors in the effectiveness of any antimicrobial product during an outbreak.

This advice is general in nature, and should be considered in conjunction with your facility's Infection Control policies and practices.

Should you have any further question please do not hesitate to contact your Account Manager or our office on 08 8294 5999 or email sales@hainesmedcial.com.au

Your sincerely,

Joshua Eastaugh

Managing Director

26 Heath Street, Lonsdale South Australia 5160 T 08 8294 5999 F 08 8294 4337 E sales@hainesmedical.com.au W hainesmedical.com.au























References

- 1. Mori Y, Ono T, Miyahira Y, Nguyen VQ, Matsui T, Ishihara M. Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus. Nanoscale Res Lett. 2013;8(1):93. Published 2013 Feb 20. doi:10.1186/1556-276X-8-93 Accessed 23/03/20
- 2. N van Doremalen, et al. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. The New England Journal of Medicine. Accessed 19/03/2020 DOI: 10.1056/NEJMc2004973 (2020).
- 3. The United States Environmental Protection Agency. List N: Products with Emerging Viral Pathogens AND Human Coronavirus claims for use against SARS-CoV-2. Accessed 19/03/2020 https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-againstsars-cov-2
- 4. Galdiero S, Falanga A, Vitiello M, Cantisani M, Marra V, Galdiero M. Silver nanoparticles as potential antiviral agents. Molecules. 2011;16(10):8894-8918. Published 2011 Oct 24. doi:10.3390/molecules16108894 Accessed 23/03/20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264685/#B46-molecules-16-08894
- 5. Williams, B.C. Nanoscale silver for infection control. Nursing2014: 2014;44(5): 68-69 doi: 10.1097/01.NURSE.0000444550.50617.1d
- 6. Lv, X., Wang, P., Bai, R., Cong, Y., Suo, S., Ren, X., & Chen, C. (2014). Inhibitory effect of silver nanomaterials on transmissible virus-induced host cell infections. Biomaterials, 35(13), 4195–4203. https://doi.org/10.1016/j.biomaterials.2014.01.054 Accessed 23/03/20
- 7. Rai, Mahendra & Deshmukh, Shivaji & Ingle, Avinash & Gupta, Indar & Galdiero, M. & Galdiero, Stefania. (2014). Metal nanoparticles: the protective shield against virus infection. Crit Rev Microbiol. 1-11 Accessed 20/03/2020 https://www.researchgate.net/publication/303157084 Metal nanoparticles the protectiv e shield against virus infection







